This study is for people with a type of colon cancer called *untreated T4N0 or Stage III dMMR/MSI-H resectable colon cancer*. **Perioperative dostarlimab** is a new medicine being tested to see if it works better than the standard treatment. The term *perioperative* means the time around surgery. *Dostarlimab* is a type of drug that helps the immune system fight cancer. *dMMR/MSI-H* refers to specific changes in the cancer cells that make them grow differently. This study is for people who have not started any treatment yet and whose cancer can be removed by surgery.
Key Points:
- Eligibility: Must have specific colon cancer, no prior treatments, and no distant spread.
- Visits and Duration: Details on how often you'll visit or how long the study lasts are not mentioned, but involvement means regular check-ups.
- Risks: Must not have severe allergies to the treatment or any other unstable health conditions.
Consider joining if you meet the criteria and want to try a new treatment option.
How understandable was the trial content above?
Hard to understand
Easy to understand